TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3555650

Group type: EXPERIMENTAL
Intervention: Chemotherapy with chlorambucil and prednisone (CP)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Fractionated total body irradiation (TBI)
Number of subjects: 108
Study: 29619838

Group type: EXPERIMENTAL
Intervention: Supervised endurance/resistance training (ET)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: L-homoarginine (L-hArg) levels
Number of subjects: 62
Study: 29115868

Group type: EXPERIMENTAL
Intervention: Collaborative care intervention for post-concussive symptoms
Number of subjects: 49
Study: 25122097

Group type: EXPERIMENTAL
Intervention: Task-oriented therapy with personalized resistance (TOT_ST group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Task-oriented therapy without load (TOT group)
Number of subjects: 20
Study: 22921881

Group type: EXPERIMENTAL
Intervention: Statin discontinuation
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Statin rechallenge
Number of subjects: 18
Study: 20804498

Group type: EXPERIMENTAL
Intervention: Pralidoxime (700 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pralidoxime (350 mg), Atropine (2 mg), Avizafone (20 mg)
Number of subjects: 0
Study: 17591020

Group type: EXPERIMENTAL
Intervention: peginterferon-alpha2b
Number of subjects: 8
Study: 15705641

Group type: EXPERIMENTAL
Intervention: Linezolid 600 mg every 12 h
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Teicoplanin 400 mg every 12 h
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Both agents
Number of subjects: 54
Study: 12010590

Group type: EXPERIMENTAL
Intervention: High-energy preload (2513 kJ)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Low-energy preload (1008 kJ)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Non-exercisers
Number of subjects: 23

Group type: COMPARATOR
Intervention: Self-ratings of hunger
Number of subjects: 23
Study: 9700174

Group type: EXPERIMENTAL
Intervention: Deferiprone
Number of subjects: 39

Group type: COMPARATOR
Intervention: Deferoxamine
Number of subjects: 39
Study: 7637721

Group type: COMPARATOR
Intervention: Intravenous ganciclovir (5 mg/kg daily)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Oral ganciclovir (3000 mg daily)
Number of subjects: 123
Study: 2692819

Group type: EXPERIMENTAL
Intervention: Diflunisal (500 mg orally, twice daily)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Naproxen (375 mg orally, twice daily)
Number of subjects: 33
Study: 832528

Group type: EXPERIMENTAL
Intervention: Fosfomycin, total dose of 4 g (2g/4h)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Fosfomycin, single dose of 4 g (2 g in each buttock)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Fosfomycin, 2g/8h for 2 days
Number of subjects: 70

Group type: COMPARATOR
Intervention: Single dose of 4 g (control for failures)
Number of subjects: 70
Study: 30846834

Group type: EXPERIMENTAL
Intervention: light-intensity treadmill walking
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: moderate-intensity treadmill walking
Number of subjects: 8

Group type: COMPARATOR
Intervention: prolonged uninterrupted sitting
Number of subjects: 8
Study: 29719302

Group type: EXPERIMENTAL
Intervention: Combination of Bevacizumab (10 mg/kg IV every 14 days) and Erlotinib (150 mg orally daily)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combination of Bevacizumab and Erlotinib
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sorafenib (400 mg orally twice daily)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combination of Bevacizumab and Erlotinib among Child‐Pugh class A patients
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sorafenib among Child‐Pugh class A patients
Number of subjects: 90
Study: 27102490

Group type: EXPERIMENTAL
Intervention: Sevelamer (SVL)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Calcium-based phosphate binders (CPiB)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Comparison of EAT progression between SVL and CPiB
Number of subjects: 109
Study: 23354743

Group type: COMPARATOR
Intervention: Control + Clearfil SE Bond (SE)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control + Single Bond (SB)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: diamond bur (DB) + SE
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: DB + SB
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Er:YAG laser (2.94 μm, 60 mJ, 2 Hz, 0.12 W, 19.3 J/cm(2)) + SE
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Er:YAG + SB
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser (2.78 μm, 50 mJ, 30 Hz, 1.5 W, 4.5 J/cm(2)) + SE
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG + SB
Number of subjects: 96
Study: 21913014

Group type: EXPERIMENTAL
Intervention: MBSR-based cancer recovery and wellness program
Number of subjects: 68

Group type: COMPARATOR
Intervention: Waitlisted control group
Number of subjects: 68
Study: 20618247

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Depot medroxyprogesterone acetate (MPA)
Number of subjects: 30
Study: 17652689

Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no aminophylline)
Number of subjects: 0
Study: 16054554

Group type: EXPERIMENTAL
Intervention: Group care
Number of subjects: 62

Group type: COMPARATOR
Intervention: Traditional one-to-one care
Number of subjects: 62
Study: 12143912

Group type: EXPERIMENTAL
Intervention: Direct switch to olanzapine (10 mg/day for 6 weeks)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Start‐taper switch to olanzapine (10 mg/day for 6 weeks) with decreasing doses of usual antipsychotic for first 2 weeks
Number of subjects: 108

Group type: COMPARATOR
Intervention: Both switch techniques
Number of subjects: 108
Study: 10201422

Group type: EXPERIMENTAL
Intervention: 60 mg/day mianserin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 7784029

Group type: EXPERIMENTAL
Intervention: Measured amniotic fluid index (AFI) on admission
Number of subjects: 447

Group type: COMPARATOR
Intervention: No sonographic assessment of amniotic fluid (AF) volume
Number of subjects: 447
Study: 2213394

Group type: EXPERIMENTAL
Intervention: Nebulized albuterol (0.15 mg/kg/dose)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 40
Study: 468583

Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin (3x5000 IU, starting 2 hours preoperatively)
Number of subjects: 1069

Group type: COMPARATOR
Intervention: Intravenous dextran (3x500 ml of 6% dextran 70)
Number of subjects: 1069
Study: 31563627

Group type: EXPERIMENTAL
Intervention: Early colonoscopy (within 24 hours)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Elective colonoscopy (24-96 hours)
Number of subjects: 170
Study: 31464771

Group type: EXPERIMENTAL
Intervention: Off-pump CABG (OPCAB) procedures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total arterial revascularization using composite bilateral internal mammary artery-Y-conduits
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open vein-graft harvesting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Endoscopic vein-graft harvesting
Number of subjects: 0
Study: 28122717

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT) - 7 × 1 min at 85% maximal aerobic power output, separated by 1 min of recovery
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 19
Study: 25884325

Group type: EXPERIMENTAL
Intervention: CTI+PVI ablation (group 2)
Number of subjects: 216

Group type: COMPARATOR
Intervention: CTI alone (group 1)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: CTI+PVI ablation (group 2) in patients aged ≥55
Number of subjects: 216

Group type: COMPARATOR
Intervention: CTI alone (group 1) in patients aged ≥55
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: CTI+PVI ablation (group 2) in patients aged <55
Number of subjects: 216

Group type: COMPARATOR
Intervention: CTI alone (group 1) in patients aged <55
Number of subjects: 216
Study: 24069230

Group type: EXPERIMENTAL
Intervention: Opal-HIV-Gag(c) 12 mg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Opal-HIV-Gag(c) 24 mg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Opal-HIV-Gag(c) 48 mg
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 21840601

Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.5 mg capsules
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tacrolimus 5 mg capsules
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tacrolimus test formulations
Number of subjects: 0
Study: 19150378

Group type: EXPERIMENTAL
Intervention: Neonatal 7-valent pneumococcal conjugate vaccine (7vPCV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (7vPCV at 1 and 2 months of age only)
Number of subjects: 0
Study: 18044435

Group type: EXPERIMENTAL
Intervention: One dose, vaccinated once at reimplant (day 42)
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: Two doses, vaccinated on arrival (day 0) and again at reimplant (day 42)
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: Three doses, vaccinated on arrival (day 0), on day 21, and again at reimplant (day 42)
Number of subjects: 608

Group type: COMPARATOR
Intervention: Unvaccinated external controls
Number of subjects: 608
Study: 15761083

Group type: EXPERIMENTAL
Intervention: Exercise in supine posture within a lower body negative pressure (LBNP) chamber for 45 min/day, 6 days/week.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nonexercise control (Con) group.
Number of subjects: 24
Study: 12474317

Group type: EXPERIMENTAL
Intervention: Tone training
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Phoneme training
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study: 9872488

Group type: EXPERIMENTAL
Intervention: Nifedipine (30‐60 mg/day) for mild to moderate hypertension for at least 1 year
Number of subjects: 85

Group type: COMPARATOR
Intervention: Normotensive women (Control group)
Number of subjects: 85
Study: 7646404

Group type: EXPERIMENTAL
Intervention: Countermeasures including repeated LBNP sequences and physical training from the 8th until the 28th day.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no countermeasures).
Number of subjects: 12
Study: 2642620

Group type: EXPERIMENTAL
Intervention: Relaxation/imagery audiotape intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 8813

Group type: EXPERIMENTAL
Intervention: Triazolam 0.5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Flurazepam 30 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30943962

Group type: EXPERIMENTAL
Intervention: App with detailed feedback (n = 231)
Number of subjects: 463

Group type: COMPARATOR
Intervention: App without detailed feedback (n = 232)
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Moderate and intensive users of the app
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Non-users of the app
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 463
Study: 28393816

Group type: EXPERIMENTAL
Intervention: Endodontic pluggers
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Lentulospirals
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: NaviTips
Number of subjects: 38
Study: 25068676

Group type: EXPERIMENTAL
Intervention: Pedometer group
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 84
Study: 23542611

Group type: EXPERIMENTAL
Intervention: 360 mg/m2 epratuzumab
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 720 mg/m2 epratuzumab
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 360 mg/m2 epratuzumab in SL0006
Number of subjects: 90
Study: 21741309

Group type: EXPERIMENTAL
Intervention: Dignity therapy
Number of subjects: 441

Group type: COMPARATOR
Intervention: Client‐centred care
Number of subjects: 441

Group type: COMPARATOR
Intervention: Standard palliative care
Number of subjects: 441
Study: 19826285

Group type: EXPERIMENTAL
Intervention: Exercise 4 or more times/week
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Exercise 3 to 4 times/week
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Exercise less than 2 times/week
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 90
Study: 16713070

Group type: EXPERIMENTAL
Intervention: Holmium laser enucleation of the prostate (HoLEP)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Open prostatectomy (OP)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Holmium laser enucleation of the prostate (HoLEP) and Open prostatectomy (OP)
Number of subjects: 80
Study: 15001257

Group type: COMPARATOR
Intervention: EBRT + PCV (non-BUdR patients)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: EBRT/BUdR + PCV (BUdR patients)
Number of subjects: 268
Study: 11337625

Group type: EXPERIMENTAL
Intervention: Methylprednisolone and bupivacaine combination
Number of subjects: 160

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 160
Study: 9218185

Group type: EXPERIMENTAL
Intervention: Swimming training
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study: 7955255

Group type: EXPERIMENTAL
Intervention: Patients with RVVO
Number of subjects: 20

Group type: COMPARATOR
Intervention: Age-matched healthy subjects
Number of subjects: 20
Study: 3310586

Group type: EXPERIMENTAL
Intervention: Moricizine HCl (816 ± 103 mg daily)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Propranolol (120 mg daily)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Moricizine HCl (800 mg daily)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Disopyramide (600 mg daily)
Number of subjects: 45
Study: 29895491

Group type: EXPERIMENTAL
Intervention: Silymarin 140 mg, thrice daily for 45 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 28539413

Group type: EXPERIMENTAL
Intervention: Unconditional cash transfers (UCT) of 10,000 West African Financial Community of Africa francs (∼US$17) provided monthly from July to November over 2 years (2013 and 2014).
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 32
Study: 26288091

Group type: EXPERIMENTAL
Intervention: Online Hemodiafiltration (HDF)
Number of subjects: 714

Group type: COMPARATOR
Intervention: Low-flux Hemodialysis (HD)
Number of subjects: 714
Study: 24024358

Group type: EXPERIMENTAL
Intervention: 1990 coal ban
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1995 coal ban
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1998 coal ban
Number of subjects: 0
Study: 20308169

Group type: EXPERIMENTAL
Intervention: DEX 1.0 microg/kg load or DEX 0.5 microg/kg load
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: DEX (both dosages)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: DEX
Number of subjects: 55

Group type: COMPARATOR
Intervention: Midazolam (MDZ)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Normal saline infusion
Number of subjects: 55
Study: 18447212

Group type: COMPARATOR
Intervention: Fluoxetine (20 mg daily)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Electroacupuncture (Baihui and Yintang points)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Electroacupuncture plus Fluoxetine
Number of subjects: 75
Study: 16373776

Group type: EXPERIMENTAL
Intervention: Internally cooled electrode
Number of subjects: 74

Group type: COMPARATOR
Intervention: Expandable electrode
Number of subjects: 74
Study: 12690216

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (target plasma level 0.4 ng/mL)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Meperidine (target plasma level 0.3 microg/mL)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Meperidine plus dexmedetomidine (target plasma levels of 0.3 microg/mL and 0.4 ng/mL)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 10
Study: 11064625

Group type: EXPERIMENTAL
Intervention: remifentanil 2 micrograms kg‐1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: remifentanil 4 micrograms kg‐1
Number of subjects: 60

Group type: COMPARATOR
Intervention: succinylcholine 1 mg kg‐1
Number of subjects: 60
Study: 8729586

Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1575006

Group type: EXPERIMENTAL
Intervention: TIA group
Number of subjects: 101

Group type: COMPARATOR
Intervention: Minor stroke group
Number of subjects: 101
Study: 4006376

Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 29171139

Group type: EXPERIMENTAL
Intervention: linagliptin 1 mg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: linagliptin 5 mg
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 27643296

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg + Amlodipine 5 mg (L/A group)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Losartan 50 mg + Hydrochlorothiazide 12.5 mg (L/H group)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg + Amlodipine 100 mg (L/A group)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Losartan 50 mg + Hydrochlorothiazide 100 mg (L/H group)
Number of subjects: 220
Study: 23477573

Group type: EXPERIMENTAL
Intervention: Infrasound exposure
Number of subjects: 54

Group type: COMPARATOR
Intervention: Sham infrasound exposure
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Low-expectancy group
Number of subjects: 54
Study: 23136163

Group type: EXPERIMENTAL
Intervention: CABG plus MVR
Number of subjects: 73

Group type: COMPARATOR
Intervention: CABG only
Number of subjects: 73
Study: 20336076

Group type: EXPERIMENTAL
Intervention: Poractant alfa
Number of subjects: 52

Group type: COMPARATOR
Intervention: Beractant
Number of subjects: 52
Study: 18762494

Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray with counseling for 8 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Weekly counseling alone for 8 weeks
Number of subjects: 40
Study: 15983465

Group type: EXPERIMENTAL
Intervention: Alfentanil infusion (30-min duration)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo infusion (30-min duration)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Noxious thermal heat
Number of subjects: 16
Study: 12954254

Group type: EXPERIMENTAL
Intervention: Endoscopic carpal tunnel release
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open carpal tunnel release
Number of subjects: 0
Study: 12365120

Group type: EXPERIMENTAL
Intervention: Wound drainage
Number of subjects: 440

Group type: COMPARATOR
Intervention: Non-drainage
Number of subjects: 440
Study: 9058355

Group type: EXPERIMENTAL
Intervention: Intervention (brief 10-min study intervention)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (pooled participants)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Baseline tobacco use variables (Fagerstrom Test for Nicotine Dependence)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Stage of readiness to quit smoking
Number of subjects: 90
Study: 2067505

Group type: EXPERIMENTAL
Intervention: Norepinephrine 10 micrograms
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Phenylephrine 100 micrograms
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Epinephrine 10 micrograms
Number of subjects: 30
Study: 7049584

Group type: EXPERIMENTAL
Intervention: 400 mg acebutolol alone
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 400 mg acebutolol + hydrochlorothiazide/amiloride diuretic
Number of subjects: 32

Group type: COMPARATOR
Intervention: hydrochlorothiazide/amiloride diuretic
Number of subjects: 32
Study: 31984646

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg/day
Number of subjects: 280

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 280
Study: 31082899

Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy
Number of subjects: 123

Group type: COMPARATOR
Intervention: Standard wound closure
Number of subjects: 123
Study: 28241153

Group type: EXPERIMENTAL
Intervention: Magnesium oxide
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94

Group type: COMPARATOR
Intervention: Comparison between Magnesium oxide and Placebo
Number of subjects: 94
Study: 26426636

Group type: EXPERIMENTAL
Intervention: Acoustic radiation force impulse (ARFI) technique measuring shear wave velocity (SWV) at baseline and predetermined time points (1 week, 6 months, and 12 months after transplantation)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Acoustic radiation force impulse (ARFI) technique measuring shear wave velocity (SWV)
Number of subjects: 91
Study: 23260805

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 130
Study: 21424274

Group type: EXPERIMENTAL
Intervention: Downhill running (DH1)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Level run (L)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Downhill running (DH2)
Number of subjects: 12
Study: 19862985

Group type: EXPERIMENTAL
Intervention: Posterior Lumbar Fusion (PLF)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Posterior Lumbar Interbody Fusion (PLIF)
Number of subjects: 30
Study: 17762365

Group type: EXPERIMENTAL
Intervention: LBNP(ex) exercise (40‐min interval at 40‐80% pre‐bed rest VO2peak, 55 +/- 4 mm Hg), 6 d.wk(‐1)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (CON) with no exercise
Number of subjects: 16
Study: 15046404

Group type: EXPERIMENTAL
Intervention: Aromatherapy massage (lavender essential oil with inert carrier oil)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Massage alone (inert carrier oil only)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Combined massage (aromatherapy and massage)
Number of subjects: 42

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 42
Study: 14685830

Group type: EXPERIMENTAL
Intervention: X STOP Interspinous Process Distraction System
Number of subjects: 200

Group type: COMPARATOR
Intervention: NON OP (non-operative therapy)
Number of subjects: 200